GlassScriptPhysician profile
Erin M Baker
NPI 1114230133
$4,364.63
in general payments reported to CMS, 2019-2025
25 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.98 · 2024: $2,112 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705 · Consulting Fee: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.63 |
| Consulting Fee | $660.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $906.92 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $660.00 | 2024 | Dupixent |
| Novo Nordisk INC | $514.28 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.28 | 2024-2025 | Caplyta |
| Abbvie INC. | $252.36 | 2024-2025 | |
| Pfizer INC. | $230.26 | 2024-2025 | |
| Lilly USA, LLC | $213.63 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Vanda Pharmaceuticals INC. | $210.91 | 2025 | Fanapt |
| Astellas Pharma US INC | $176.81 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $164.85 | 2024-2025 | Rexulti |
| Orexo US, INC. | $83.76 | 2024-2025 | Zubsolv |
| Lundbeck LLC | $81.59 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $77.13 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $72.40 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $67.40 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.14 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.56 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $32.80 | 2024-2025 | Eliquis |
| Indivior INC. | $28.73 | 2025 | Sublocade |
| Sumitomo Pharma America, INC. | $24.31 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $21.89 | 2025 | |
| Currax Pharmaceuticals LLC | $15.98 | 2024 | Contrave |
| Abbott Laboratories | $14.29 | 2024 | Freestyle Libre 3 |
| Irhythm Technologies, INC. | $13.68 | 2024 | Zio Monitor, Zio Xt Patch |
| Kowa Pharmaceuticals America, INC. | $13.67 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.